Protagonist Craters After Discontinuing Phase IIb Ulcerative Colitis Study

Shares of Protagonist Therapeutics plunged more than 60 percent in pre-market trading after the company announced it will discontinue its Phase IIb ulcerative colitis treatment after a review from an Independent Data Monitoring Committee (DMC).
Source: BioSpace